Up­dat­ed: Mer­ck look­ing at Seagen takeover bid in the wake of Clay Sie­gal­l's res­ig­na­tion — re­port

Mer­ck is eval­u­at­ing a po­ten­tial buy­out of em­bat­tled Seat­tle biotech Seagen, ac­cord­ing to a re­port from the Wall Street Jour­nal on Fri­day morn­ing.

This is the newest de­vel­op­ment for the biotech af­ter for­mer CEO Clay Sie­gall stepped down from the com­pa­ny — while al­so for­feit­ing his board po­si­tions at oth­er com­pa­nies such as Umo­ja Bio­phar­ma — fol­low­ing al­le­ga­tions of do­mes­tic vi­o­lence that sur­faced last month. He was ini­tial­ly ar­rest­ed in the ear­ly hours of April 23 af­ter a phys­i­cal al­ter­ca­tion with his wife left her with mul­ti­ple bruis­es, ac­cord­ing to a po­lice re­port. Sie­gall has de­nied the al­le­ga­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER